- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
Home
DNA Damage/DNA Repair
DNA/RNA Synthesis inhibitor
-
Autophagy activator
-
Apoptosis related activator
-
Nucleoside Analog/Antimetabolite inhibitor
Cytarabine
僅限科研使用
Cytarabine
別名: Cytarabin,Ara-C,Arabinofuranosyl Cytidine,Cytosine β-D-arabinofuranoside,Cytosine arabinoside,NSC 63878,NSC 287459,U-19920A 中文名稱：阿糖胞苷, 阿糖胞嘧啶
Cytarabine是一種抗代謝藥，也是DNA synthesis抑制劑，在野生型CCRF-CEM細胞中IC50為16 nM。Cytarabine 可誘導自噬和細胞凋亡。
Cytarabine Chemical Structure
CAS: 147-94-4
產(chǎn)品質(zhì)控
批次：
純度：
99.99%
99.99
常與Cytarabine一起在實驗中被使用的化合物
Cytarabine和Venetoclax可對患有急性髓性白血病(AML)的老年人產(chǎn)生快速且持久的緩解。
Wei AH, et al. J Clin Oncol. 2019 May 20; 37(15): 1277–1284.
低劑量Cytarabine和Azacitidine對患有急性髓性白血病和高骨髓母細胞計數(shù)的姑息患者療效有限。
在治療兒科AML中，Cytarabine和Decitabine在減輕腫瘤負荷方面比單獨使用任何一種藥物更有效。
Cytarabine和Daunorubicin HCl脂質(zhì)體制劑被批準用于治療急性髓系白血病(AML)。
Voreloxin (SNS-595) hydrochloride
Cytarabine和Voreloxin?hydrochloride在體外和體內(nèi)均表現(xiàn)出細胞毒活性。
Scatena CD, et al. Cancer Chemother Pharmacol. 2010 Oct;66(5):881-8.
Cytarabine相關(guān)產(chǎn)品
相關(guān)信號通路圖
細胞實驗數(shù)據(jù)示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
|---|---|---|---|---|---|
| KG1 | Antitumor assay | 100 mg/kg | 11 days | Antitumor activity against human KG1 cells xenografted in mouse assessed as tumor regression at 100 mg/kg, po qd measured after 11 days post tumor implantation | 26505898 |
| L1210/0 | Cytotoxicity assay | 48 hrs | Cytotoxicity against mouse L1210/0 cells after 48 hrs, IC50 = 0.7 μM. | 17341060 | |
| P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay, IC50 = 1.233 μM. | 2778449 | |
| HT-29 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay, IC50 = 0.066 μM. | 2778449 | |
| HDF | Growth inhibition assay | 72 hrs | Growth inhibition of HDF cells after 72 hrs by WST-1 assay, GI50 = 0.25 μM. | 22264170 | |
| NUGC3 | Growth inhibition assay | 24 hrs | Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay, GI50 = 0.25 μM. | 22264170 | |
| HUVEC | Growth inhibition assay | 72 hrs | Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay, GI50 = 0.23 μM. | 22264170 | |
| A549 | Growth inhibition assay | 24 hrs | Growth inhibition of human A549 cells after 24 hrs by WST-1 assay, GI50 = 0.2 μM. | 22264170 | |
| HeLa | Growth inhibition assay | 24 hrs | Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay, GI50 = 0.18 μM. | 22264170 | |
| HCT116 | Growth inhibition assay | 24 hrs | Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay, GI50 = 0.12 μM. | 22264170 | |
| BALL-1 | Growth inhibition assay | 24 hrs | Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay, GI50 = 0.08 μM. | 22264170 | |
| BGM | Antiviral assay | 5 days | Antiviral activity against Herpes Simplex virus HF infected in African green monkey BGM cells assessed as plaque reduction measured on day 5 by disk diffusion assay, ED50 = 0.16 μM. | 178873 | |
| BGM | Antiviral assay | 5 days | Antiviral activity against Vaccinia virus IHD infected in African green monkey BGM cells assessed as plaque reduction measured on day 5 by disk diffusion assay, ED50 = 0.07 μM. | 178873 | |
| L1210 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay, ED50 = 0.1 μM. | 118258 | |
| HL60 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay, EC50 = 0.6572 μM. | 19743858 | |
| HL60/MX2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay, EC50 = 0.2612 μM. | 19743858 | |
| CCRF-CEM/C2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay, EC50 = 0.0228 μM. | 19743858 | |
| CCRF-CEM | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay, EC50 = 0.005614 μM. | 19743858 | |
| P388 murine cell lines | Function assay | 72 h | The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against the P388 murine cell lines after 72 hours, ID50=20 nM. | 3625714 | |
| L1210 murine cell lines | Function assay | 72 h | The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against the L1210 murine cell lines after 72 hours, ID50=20 nM. | 3625714 | |
| HeLa human cell lines | Function assay | 144 h | The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against HeLa human cell lines after 144 hr, ID50=0.1 μM | 3625714 | |
| CCRF-CEM cell lines | Function assay | 72 h | Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation, ED50=6 nM. | 1652024 | |
| HL60 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HL60 cells after 48 hrs by MTT assay, IC50 = 0.118 μM. | 19321234 | |
| L1210 | Cytotoxicity assay | 3 days | Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay, IC50 = 0.0004 μM. | 19674903 | |
| CCRF-CEM | Cytotoxicity assay | 3 days | Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay, IC50 = 0.001 μM. | 19674903 | |
| MCF7 | Cytotoxicity assay | 3 days | Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay, IC50 = 0.004 μM. | 19674903 | |
| MCF7 1K | Cytotoxicity assay | 3 days | Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay, IC50 = 0.04 μM. | 19674903 | |
| MESSA | Cytotoxicity assay | 3 days | Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay, IC50 = 1.7 μM. | 19674903 | |
| L1210 | Cytotoxicity assay | 2 days | Cytotoxicity against mouse L1210 cells after 2 days, IC50 = 0.024 μM. | 19910080 | |
| CEM | Cytotoxicity assay | 2 days | Cytotoxicity against human CEM cells after 2 days, IC50 = 0.024 μM. | 19910080 | |
| CEM | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs, IC50 = 0.024 μM. | 20000418 | |
| L1210 | Cytotoxicity assay | 48 hrs | Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs, IC50 = 0.024 μM. | 20000418 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs, IC50 = 0.26 μM. | 20000418 | |
| RS4:11 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay, IC50 = 0.26 μM. | 20153646 | |
| MV411 | Antiproliferative assay | 72 hrs | Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay, IC50 = 3.36 μM. | 20153646 | |
| HCT116 | Antitumor assay | 24 hrs | Antitumor activity against human HCT116 cells after 24 hrs by MTT assay, IC50 = 0.1 μM. | 20211564 | |
| H460 | Antitumor assay | 24 hrs | Antitumor activity against human H460 cells after 24 hrs by MTT assay, IC50 = 0.1 μM. | 20211564 | |
| MOLT4 | Antitumor assay | 24 hrs | Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay, IC50 = 1 μM. | 20211564 | |
| SW620 | Antitumor assay | 24 hrs | Antitumor activity against human SW620 cells after 24 hrs by MTT assay, IC50 = 30 μM. | 20211564 | |
| SF268 | Cytotoxicity assay | 3 days | Cytotoxicity against human SF268 cells after 3 days by MTT assay, IC50 = 7.68 μM. | 20356655 | |
| SFME | Antiproliferative assay | 24 hrs | Antiproliferative activity against mouse SFME cells after 24 hrs by MTT assay, IC50 = 0.8 μM. | 20398972 | |
| HM-SFME-1 | Antiproliferative assay | 24 hrs | Antiproliferative activity against mouse r/m HM-SFME-1 cells after 24 hrs by MTT assay, IC50 = 33.3 μM. | 20398972 | |
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay, IC50 = 0.2 μM. | 20692841 | |
| K562 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human K562 cells after 24 hrs by MTT assay, IC50 = 33.5 μM. | 20692841 | |
| Bel7402 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay, IC50 = 34.2 μM. | 20692841 | |
| K562 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human K562 cells after 48 hrs by MTT assay, IC50 = 24.29 μM. | 21620529 | |
| S180 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay, IC50 = 25.43 μM. | 21620529 | |
| H22 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay, IC50 = 25.98 μM. | 21620529 | |
| HepG2 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay, IC50 = 26.23 μM. | 21620529 | |
| B16 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay, IC50 = 30.62 μM. | 21620529 | |
| CCRF-CEM | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50 = 0.006 μM. | 22582991 | |
| HL60 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50 = 0.049 μM. | 22582991 | |
| K562 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50 = 14 μM. | 22582991 | |
| blood stem/progenitor cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CD34-positive blood stem/progenitor cells after 48 hrs by MTT assay, IC50 = 0.59 μM. | 23578690 | |
| MA9.3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MA9.3 cells after 48 hrs by MTT assay, IC50 = 0.92 μM. | 23578690 | |
| HeLa | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HeLa cells after 72 hrs by SRB assay, IC50 = 3.54 μM. | 23867603 | |
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay, IC50 = 3.82 μM. | 23867603 | |
| KB | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50 = 4.07 μM. | 23867603 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay, IC50 = 1.2 μM. | 26010585 | |
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay, IC50 = 1.37 μM. | 26010585 | |
| SKHEP1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay, IC50 = 2.12 μM. | 26010585 | |
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay, IC50 = 2.42 μM. | 26010585 | |
| SNU638 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay, IC50 = 3.98 μM. | 26010585 | |
| 143B | Cytotoxicity assay | 72 hrs | Cytotoxicity against human 143B cells after 72 hrs by SRB assay, IC50 = 2.06 μM. | 27073055 | |
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay, IC50 = 2.86 μM. | 27073055 | |
| HeLa | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HeLa cells after 72 hrs by SRB assay, IC50 = 3.54 μM. | 27073055 | |
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7cells after 72 hrs by SRB assay, IC50 = 3.82 μM. | 27073055 | |
| KB | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50 = 4.07 μM. | 27073055 | |
| HDF | Cytotoxicity assay | 72 hrs | Cytotoxicity against HDF cells after 72 hrs by SRB assay, IC50 = 4.99 μM. | 27073055 | |
| thymidine kinase deficient 143B | Cytotoxicity assay | 72 hrs | Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay, IC50 = 16.88 μM. | 27073055 | |
| SMMC7721 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay, IC50 = 0.013 μM. | 29886320 | |
| LO2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay, IC50 = 0.17 μM. | 29886320 | |
| SNU638 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay, IC50 = 1.08 μM. | 29906687 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay, IC50 = 1.75 μM. | 29906687 | |
| SKHEP1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay, IC50 = 1.8 μM. | 29906687 | |
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay, IC50 = 4.4 μM. | 29906687 | |
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay, IC50 = 10.49 μM. | 29906687 | |
| PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay, IC50 = 48.4 μM. | 29906687 | |
| BL21(DE3) | Function assay | 3 mins | Activity of human recombinant N-terminal His-tagged DCK Pro122Ser mutant expressed in Escherichia coli BL21(DE3) cells assessed as cytosine-beta-D-arabinofuranoside-5'-MP formation incubated for 3 mins by liquid chromatography-tandem mass spectrometry, Km = 1.56 μM. | 23230131 | |
| BL21(DE3) | Function assay | 3 mins | Activity of human recombinant N-terminal His-tagged DCK Ile24Val mutant expressed in Escherichia coli BL21(DE3) cells assessed as cytosine-beta-D-arabinofuranoside-5'-MP formation incubated for 3 mins by liquid chromatography-tandem mass spectrometry, Km = 2.45 μM. | 23230131 | |
| BL21(DE3) | Function assay | 3 mins | Activity of human recombinant N-terminal His-tagged DCK Ala119Gly mutant expressed in Escherichia coli BL21(DE3) cells assessed as cytosine-beta-D-arabinofuranoside-5'-MP formation incubated for 3 mins by liquid chromatography-tandem mass spectrometry, Km = 2.54 μM. | 23230131 | |
| BL21(DE3) | Function assay | 3 mins | Activity of human recombinant N-terminal His-tagged wild type DCK expressed in Escherichia coli BL21(DE3) cells assessed as cytosine-beta-D-arabinofuranoside-5'-MP formation incubated for 3 mins by liquid chromatography-tandem mass spectrometry, Km = 3.04 μM. | 23230131 | |
| KB | Antiviral assay | 72 hrs | Antiviral activity against Pseudorabies virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopically | 458802 | |
| KB | Antiviral assay | 72 hrs | Antiviral activity against Herpes simplex virus type 1 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopically | 458802 | |
| KB | Antiviral assay | 72 hrs | Antiviral activity against Vaccinia virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopically | 458802 | |
| KB | Antiviral assay | 72 hrs | Antiviral activity against Myxoma virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopically | 458802 | |
| KB | Growth inhibition assay | Growth inhibition of human KB cells by MTT assay, IC50 = 0.7 μM. | 17049252 | ||
| CCRF-HSB-2 | Growth inhibition assay | Growth inhibition of human CCRF-HSB-2 cells by MTT assay, IC50 = 0.15 μM. | 17049252 | ||
| HL60R | Function assay | In vitro concentration required to induce apoptosis in HL60R cells, IC50 = 0.35 μM. | 12877593 | ||
| HL60 | Function assay | In vitro inhibitory concentration against proliferation of HL60 cells, IC50 = 0.08 μM. | 12877593 | ||
| SK-MEL-28 | Cytotoxicity assay | In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells, IC50 = 1 μM. | 10780904 | ||
| SNB-7 | Cytotoxicity assay | In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1, IC50 = 1 μM. | 10780904 | ||
| NCI-H23 | Cytotoxicity assay | In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1, IC50 = 1 μM. | 10780904 | ||
| K562(S) | Growth inhibition assay | Inhibition of cell growth against human myeloid leukemia K562(S) cells, IC50 = 0.5 μM. | 10560743 | ||
| KB | Function assay | Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells, IC50 = 2.3 μM. | 8277499 | ||
| leukemia L1210 | Function assay | Inhibitory activity against murine leukemia L1210 cells, IC50 = 0.08 μM. | 1992143 | ||
| leukemia L1210 | Function assay | Inhibitory concentration on parentral (sensitive) L1210 leukemia cells., IC50 = 0.036 μM. | 1906107 | ||
| leukemia L1210 | Function assay | Inhibitory concentration on multidrug-resistant L1210 leukemia cells., IC50 = 0.036 μM. | 1906107 | ||
| leukemia L1210 | Function assay | Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr), IC50 = 0.1 μM. | 1527783 | ||
| leukemia L1210 | Function assay | Inhibition of L1210 lymphoid leukemia cells 72 hr after administration (length of preincubation=0 hr), IC50 = 0.01 μM. | 1527783 | ||
| leukemia L1210 | Function assay | Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr), IC50 = 0.01 μM. | 1527783 | ||
| L1210 | Function assay | Inhibition of thymidylate synthase in L1210 cells, ED50 = 0.03 μM. | 3027329 | ||
| HL60R | Function assay | In vitro concentration required to induce apoptosis in HL60R cells, AC50 = 8 μM. | 12877593 | ||
| HL60 | Function assay | In vitro concentration required to induce apoptosis in HL60 cells, AC50 = 0.15 μM. | 12877593 | ||
| human leukemia cell line(CCRF-CEM) | Cytotoxic?assay | In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM), IC50=0.09 μM. | 8917645 | ||
| MOLT-4 human leukemic lymphoblastoid cell lines | Cytotoxic?assay | Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines, IC50=10 nM. | 6827546 | ||
| CCRF-CEM human leukemic lymphoblastoid cell lines | Cytotoxic?assay | Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines, IC50=20 nM. | 6827546 | ||
| RPMI-6410 human leukemic lymphoblastoid cell lines | Cytotoxic?assay | Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines, IC50=0.06 μM | 6827546 | ||
| CCRF-CEM cell line | Function assay | Inhibit the replication of CCRF-CEM cell line in vitro, ED50=5 nM. | 1995894 | ||
| L1210 cell lines | Function assay | Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation, ED50=0.05 μM. | 1652024 | ||
| murine leukemia P388 | Function assay | Anticancer activity carried out in vitro against murine leukemia P388, IC50=0.14 μM | 11356110 | ||
| 2209-23 | Antiviral assay | Antiviral activity against Hepatitis C virus infected human 2209-23 cells by genotype 1b replicon assay, IC50 = 0.02 μM. | 19055482 | ||
| 2209-23 | Antiproliferative assay | Antiproliferative activity against human 2209-23 cells by [3H]thymidine incorporation scintillation proximity assay, IC50 = 0.029 μM. | 19055482 | ||
| SF268 | Cytotoxicity assay | Cytotoxicity against human SF268 cells by MTT assay, IC50 = 0.00768 μM. | 19345581 | ||
| K562 | Cytotoxicity assay | Cytotoxicity against human K562 cells by sulforhodamine B method, IC50 = 0.05 μM. | 19691349 | ||
| SNU638 | Cytotoxicity assay | Cytotoxicity against human SNU638 cells by sulforhodamine B method, IC50 = 0.15 μM. | 19691349 | ||
| A549 | Cytotoxicity assay | Cytotoxicity against human A549 cells by sulforhodamine B method, IC50 = 1.9 μM. | 19691349 | ||
| T47D | Cytotoxicity assay | Cytotoxicity against human T47D cells by sulforhodamine B method, IC50 = 2.7 μM. | 19691349 | ||
| HCT116 | Cytotoxicity assay | Cytotoxicity against human HCT116 cells by sulforhodamine B method, IC50 = 5.3 μM. | 19691349 | ||
| K562 | Cytotoxicity assay | Cytotoxicity against human K562 cells by SRB assay, IC50 = 0.05 μM. | 24956556 | ||
| SNU638 | Cytotoxicity assay | Cytotoxicity against human SNU638 cells by SRB assay, IC50 = 0.15 μM. | 24956556 | ||
| A549 | Cytotoxicity assay | Cytotoxicity against human A549 cells by SRB assay, IC50 = 1.9 μM. | 24956556 | ||
| T47D | Cytotoxicity assay | Cytotoxicity against human T47D cells by SRB assay, IC50 = 2.72 μM. | 24956556 | ||
| HCT116 | Cytotoxicity assay | Cytotoxicity against human HCT116 cells by SRB assay, IC50 = 5.3 μM. | 24956556 | ||
| HeLa | Cytotoxicity assay | Cytotoxicity against human HeLa cells, IC50 = 0.95 μM. | 29886320 | ||
| Jurkat E6-1 | Antiproliferative assay | Antiproliferative activity against human Jurkat E6-1 cells, IC50 = 0.018 μM. | 30114661 | ||
| HL60 | Antiproliferative assay | Antiproliferative activity against human HL60 cells, IC50 = 0.185 μM. | 30114661 | ||
| H441 | Cytotoxicity assay | Cytotoxicity against human H441 cells by serum lactate dehydrogenase assay | 19574048 | ||
| H441 | Cytotoxicity assay | Cytotoxicity against human H441 cells by glucosaminidase assay | 19574048 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
| P12-ICHIKAWA | Growth Inhibition Assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50 = 0.005537 μM. | SANGER | ||
| 697 | Growth Inhibition Assay | Inhibition of human 697 cell growth in a cell viability assay, IC50 = 0.0106 μM. | SANGER | ||
| ES1 | Growth Inhibition Assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50 = 0.01297 μM. | SANGER | ||
| HEL | Growth Inhibition Assay | Inhibition of human HEL cell growth in a cell viability assay, IC50 = 0.02052 μM. | SANGER | ||
| CHP-212 | Growth Inhibition Assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50 = 0.03347 μM. | SANGER | ||
| CTB-1 | Growth Inhibition Assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50 = 0.0344 μM. | SANGER | ||
| A427 | Growth Inhibition Assay | Inhibition of human A427 cell growth in a cell viability assay, IC50 = 0.03449 μM. | SANGER | ||
| MOLT-16 | Growth Inhibition Assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 0.03607 μM. | SANGER | ||
| MC-IXC | Growth Inhibition Assay | Inhibition of human MC-IXC cell growth in a cell viability assay, IC50 = 0.04141 μM. | SANGER | ||
| BHT-101 | Growth Inhibition Assay | Inhibition of human BHT-101 cell growth in a cell viability assay, IC50 = 0.04176 μM. | SANGER | ||
| K5 | Growth Inhibition Assay | Inhibition of human K5 cell growth in a cell viability assay, IC50 = 0.0432 μM. | SANGER | ||
| A549 | Growth Inhibition Assay | Inhibition of human A549 cell growth in a cell viability assay, IC50 = 0.04966 μM. | SANGER | ||
| NCI-H1703 | Growth Inhibition Assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50 = 0.04981 μM. | SANGER | ||
| LB2241-RCC | Growth Inhibition Assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50 = 0.05534 μM. | SANGER | ||
| MLMA | Growth Inhibition Assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50 = 0.05551 μM. | SANGER | ||
| P30-OHK | Growth Inhibition Assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 0.0565 μM. | SANGER | ||
| NCI-H510A | Growth Inhibition Assay | Inhibition of human NCI-H510A cell growth in a cell viability assay, IC50 = 0.06826 μM. | SANGER | ||
| J-RT3-T3-5 | Growth Inhibition Assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 0.06842 μM. | SANGER | ||
| VA-ES-BJ | Growth Inhibition Assay | Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50 = 0.07165 μM. | SANGER | ||
| T-24 | Growth Inhibition Assay | Inhibition of human T-24 cell growth in a cell viability assay, IC50 = 0.07856 μM. | SANGER | ||
| NB69 | Growth Inhibition Assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 0.07948 μM. | SANGER | ||
| CTV-1 | Growth Inhibition Assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 0.08474 μM. | SANGER | ||
| MEL-JUSO | Growth Inhibition Assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50 = 0.08576 μM. | SANGER | ||
| MOLT-4 | Growth Inhibition Assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 0.08967 μM. | SANGER | ||
| SW982 | Growth Inhibition Assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50 = 0.09123 μM. | SANGER | ||
| NCI-SNU-1 | Growth Inhibition Assay | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50 = 0.09677 μM. | SANGER | ||
| GP5d | Growth Inhibition Assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50 = 0.10205 μM. | SANGER | ||
| SAS | Growth Inhibition Assay | Inhibition of human SAS cell growth in a cell viability assay, IC50 = 0.10757 μM. | SANGER | ||
| BFTC-905 | Growth Inhibition Assay | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50 = 0.10831 μM. | SANGER | ||
| LB1047-RCC | Growth Inhibition Assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50 = 0.10842 μM. | SANGER | ||
| BB65-RCC | Growth Inhibition Assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50 = 0.11019 μM. | SANGER | ||
| KE-37 | Growth Inhibition Assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50 = 0.11085 μM. | SANGER | ||
| NCI-H292 | Growth Inhibition Assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50 = 0.1142 μM. | SANGER | ||
| HT-1080 | Growth Inhibition Assay | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50 = 0.11447 μM. | SANGER | ||
| CAKI-1 | Growth Inhibition Assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50 = 0.12001 μM. | SANGER | ||
| HMV-II | Growth Inhibition Assay | Inhibition of human HMV-II cell growth in a cell viability assay, IC50 = 0.12363 μM. | SANGER | ||
| ES8 | Growth Inhibition Assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50 = 0.12393 μM. | SANGER | ||
| NEC8 | Growth Inhibition Assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50 = 0.13421 μM. | SANGER | ||
| EW-1 | Growth Inhibition Assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50 = 0.13862 μM. | SANGER | ||
| H-EMC-SS | Growth Inhibition Assay | Inhibition of human H-EMC-SS cell growth in a cell viability assay, IC50 = 0.14528 μM. | SANGER | ||
| NTERA-S-cl-D1 | Growth Inhibition Assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50 = 0.1591 μM. | SANGER | ||
| COR-L105 | Growth Inhibition Assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 0.16039 μM. | SANGER | ||
| A2780 | Growth Inhibition Assay | Inhibition of human A2780 cell growth in a cell viability assay, IC50 = 0.16238 μM. | SANGER | ||
| C2BBe1 | Growth Inhibition Assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50 = 0.16596 μM. | SANGER | ||
| SK-UT-1 | Growth Inhibition Assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50 = 0.18142 μM. | SANGER | ||
| CGTH-W-1 | Growth Inhibition Assay | Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50 = 0.1818 μM. | SANGER | ||
| PA-1 | Growth Inhibition Assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50 = 0.18665 μM. | SANGER | ||
| NB10 | Growth Inhibition Assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50 = 0.18814 μM. | SANGER | ||
| HCC1806 | Growth Inhibition Assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50 = 0.19102 μM. | SANGER | ||
| PSN1 | Growth Inhibition Assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50 = 0.19281 μM. | SANGER | ||
| ES3 | Growth Inhibition Assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50 = 0.1987 μM. | SANGER | ||
| OVCAR-8 | Growth Inhibition Assay | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50 = 0.2108 μM. | SANGER | ||
| EM-2 | Growth Inhibition Assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 0.21139 μM. | SANGER | ||
| ES4 | Growth Inhibition Assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50 = 0.21401 μM. | SANGER | ||
| TE-8 | Growth Inhibition Assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50 = 0.2191 μM. | SANGER | ||
| OVCAR-5 | Growth Inhibition Assay | Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50 = 0.21963 μM. | SANGER | ||
| HN | Growth Inhibition Assay | Inhibition of human HN cell growth in a cell viability assay, IC50 = 0.2207 μM. | SANGER | ||
| A673 | Growth Inhibition Assay | Inhibition of human A673 cell growth in a cell viability assay, IC50 = 0.22382 μM. | SANGER | ||
| 769-P | Growth Inhibition Assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 0.22786 μM. | SANGER | ||
| LC-2-ad | Growth Inhibition Assay | Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50 = 0.22961 μM. | SANGER | ||
| SJSA-1 | Growth Inhibition Assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50 = 0.23516 μM. | SANGER | ||
| HuP-T4 | Growth Inhibition Assay | Inhibition of human HuP-T4 cell growth in a cell viability assay, IC50 = 0.23681 μM. | SANGER | ||
| ES5 | Growth Inhibition Assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50 = 0.2429 μM. | SANGER | ||
| HCT-116 | Growth Inhibition Assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 0.24477 μM. | SANGER | ||
| DB | Growth Inhibition Assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 0.24595 μM. | SANGER | ||
| LXF-289 | Growth Inhibition Assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50 = 0.25141 μM. | SANGER | ||
| ES7 | Growth Inhibition Assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50 = 0.25716 μM. | SANGER | ||
| EW-16 | Growth Inhibition Assay | Inhibition of human EW-16 cell growth in a cell viability assay, IC50 = 0.26588 μM. | SANGER | ||
| LU-99A | Growth Inhibition Assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50 = 0.26643 μM. | SANGER | ||
| D-566MG | Growth Inhibition Assay | Inhibition of human D-566MG cell growth in a cell viability assay, IC50 = 0.26904 μM. | SANGER | ||
| ML-2 | Growth Inhibition Assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 0.26965 μM. | SANGER | ||
| H4 | Growth Inhibition Assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 0.27445 μM. | SANGER | ||
| HCE-4 | Growth Inhibition Assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50 = 0.27713 μM. | SANGER | ||
| ALL-PO | Growth Inhibition Assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50 = 0.28709 μM. | SANGER | ||
| SNU-387 | Growth Inhibition Assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50 = 0.28877 μM. | SANGER | ||
| LOXIMVI | Growth Inhibition Assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 0.29031 μM. | SANGER | ||
| YKG-1 | Growth Inhibition Assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 0.29831 μM. | SANGER | ||
| D-423MG | Growth Inhibition Assay | Inhibition of human D-423MG cell growth in a cell viability assay, IC50 = 0.29851 μM. | SANGER | ||
| KYSE-510 | Growth Inhibition Assay | Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50 = 0.30633 μM. | SANGER | ||
| NB14 | Growth Inhibition Assay | Inhibition of human NB14 cell growth in a cell viability assay, IC50 = 0.30956 μM. | SANGER | ||
| A204 | Growth Inhibition Assay | Inhibition of human A204 cell growth in a cell viability assay, IC50 = 0.31068 μM. | SANGER | ||
| 23132-87 | Growth Inhibition Assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50 = 0.31872 μM. | SANGER | ||
| Ca9-22 | Growth Inhibition Assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 0.32077 μM. | SANGER | ||
| MHH-ES-1 | Growth Inhibition Assay | Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50 = 0.32338 μM. | SANGER | ||
| MSTO-211H | Growth Inhibition Assay | Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50 = 0.32388 μM. | SANGER | ||
| YH-13 | Growth Inhibition Assay | Inhibition of human YH-13 cell growth in a cell viability assay, IC50 = 0.32755 μM. | SANGER | ||
| HAL-01 | Growth Inhibition Assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50 = 0.32786 μM. | SANGER | ||
| RH-1 | Growth Inhibition Assay | Inhibition of human RH-1 cell growth in a cell viability assay, IC50 = 0.32816 μM. | SANGER | ||
| LAMA-84 | Growth Inhibition Assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 0.33454 μM. | SANGER | ||
| NBsusSR | Growth Inhibition Assay | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50 = 0.3354 μM. | SANGER | ||
| JAR | Growth Inhibition Assay | Inhibition of human JAR cell growth in a cell viability assay, IC50 = 0.33788 μM. | SANGER | ||
| GI-1 | Growth Inhibition Assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50 = 0.33883 μM. | SANGER | ||
| RPMI-7951 | Growth Inhibition Assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50 = 0.33952 μM. | SANGER | ||
| 8-MG-BA | Growth Inhibition Assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50 = 0.3407 μM. | SANGER | ||
| GT3TKB | Growth Inhibition Assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 0.34071 μM. | SANGER | ||
| UM-UC-3 | Growth Inhibition Assay | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50 = 0.34227 μM. | SANGER | ||
| U-2-OS | Growth Inhibition Assay | Inhibition of human U-2-OS cell growth in a cell viability assay, IC50 = 0.34387 μM. | SANGER | ||
| SW620 | Growth Inhibition Assay | Inhibition of human SW620 cell growth in a cell viability assay, IC50 = 0.3492 μM. | SANGER | ||
| HOP-92 | Growth Inhibition Assay | Inhibition of human HOP-92 cell growth in a cell viability assay, IC50 = 0.3544 μM. | SANGER | ||
| BFTC-909 | Growth Inhibition Assay | Inhibition of human BFTC-909 cell growth in a cell viability assay, IC50 = 0.35736 μM. | SANGER | ||
| D-283MED | Growth Inhibition Assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50 = 0.36027 μM. | SANGER | ||
| SW48 | Growth Inhibition Assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 0.36566 μM. | SANGER | ||
| ATN-1 | Growth Inhibition Assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50 = 0.36571 μM. | SANGER | ||
| ACHN | Growth Inhibition Assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50 = 0.37018 μM. | SANGER | ||
| LS-513 | Growth Inhibition Assay | Inhibition of human LS-513 cell growth in a cell viability assay, IC50 = 0.3795 μM. | SANGER | ||
| TE-5 | Growth Inhibition Assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50 = 0.3806 μM. | SANGER | ||
| IST-MEL1 | Growth Inhibition Assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 0.3808 μM. | SANGER | ||
| RS4-11 | Growth Inhibition Assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 0.381 μM. | SANGER | ||
| GR-ST | Growth Inhibition Assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 0.38472 μM. | SANGER | ||
| NCI-H1048 | Growth Inhibition Assay | Inhibition of human NCI-H1048 cell growth in a cell viability assay, IC50 = 0.38876 μM. | SANGER | ||
| ONS-76 | Growth Inhibition Assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50 = 0.39003 μM. | SANGER | ||
| H9 | Growth Inhibition Assay | Inhibition of human H9 cell growth in a cell viability assay, IC50 = 0.39142 μM. | SANGER | ||
| GAMG | Growth Inhibition Assay | Inhibition of human GAMG cell growth in a cell viability assay, IC50 = 0.39364 μM. | SANGER | ||
| GMS-10 | Growth Inhibition Assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 0.39556 μM. | SANGER | ||
| A375 | Growth Inhibition Assay | Inhibition of human A375 cell growth in a cell viability assay, IC50 = 0.39567 μM. | SANGER | ||
| NCI-H1155 | Growth Inhibition Assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50 = 0.39685 μM. | SANGER | ||
| OC-314 | Growth Inhibition Assay | Inhibition of human OC-314 cell growth in a cell viability assay, IC50 = 0.39891 μM. | SANGER | ||
| HSC-3 | Growth Inhibition Assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50 = 0.39994 μM. | SANGER | ||
| RPMI-2650 | Growth Inhibition Assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50 = 0.40146 μM. | SANGER | ||
| SK-PN-DW | Growth Inhibition Assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50 = 0.41557 μM. | SANGER | ||
| MZ7-mel | Growth Inhibition Assay | Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50 = 0.41695 μM. | SANGER | ||
| GOTO | Growth Inhibition Assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50 = 0.42403 μM. | SANGER | ||
| COLO-800 | Growth Inhibition Assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50 = 0.42456 μM. | SANGER | ||
| NCI-H2122 | Growth Inhibition Assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50 = 0.42962 μM. | SANGER | ||
| JEG-3 | Growth Inhibition Assay | Inhibition of human JEG-3 cell growth in a cell viability assay, IC50 = 0.43108 μM. | SANGER | ||
| SK-N-AS | Growth Inhibition Assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50 = 0.45046 μM. | SANGER | ||
| NB5 | Growth Inhibition Assay | Inhibition of human NB5 cell growth in a cell viability assay, IC50 = 0.45227 μM. | SANGER | ||
| HGC-27 | Growth Inhibition Assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50 = 0.45523 μM. | SANGER | ||
| HTC-C3 | Growth Inhibition Assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 0.45932 μM. | SANGER | ||
| LK-2 | Growth Inhibition Assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50 = 0.46056 μM. | SANGER | ||
| HSC-4 | Growth Inhibition Assay | Inhibition of human HSC-4 cell growth in a cell viability assay, IC50 = 0.46741 μM. | SANGER | ||
| SW13 | Growth Inhibition Assay | Inhibition of human SW13 cell growth in a cell viability assay, IC50 = 0.47618 μM. | SANGER | ||
| LCLC-97TM1 | Growth Inhibition Assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 0.47741 μM. | SANGER | ||
| BCPAP | Growth Inhibition Assay | Inhibition of human BCPAP cell growth in a cell viability assay, IC50 = 0.50118 μM. | SANGER | ||
| 5637 | Growth Inhibition Assay | Inhibition of human 5637 cell growth in a cell viability assay, IC50 = 0.50148 μM. | SANGER | ||
| RT-112 | Growth Inhibition Assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 0.50193 μM. | SANGER | ||
| BV-173 | Growth Inhibition Assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50 = 0.51551 μM. | SANGER | ||
| HOS | Growth Inhibition Assay | Inhibition of human HOS cell growth in a cell viability assay, IC50 = 0.51822 μM. | SANGER | ||
| BT-549 | Growth Inhibition Assay | Inhibition of human BT-549 cell growth in a cell viability assay, IC50 = 0.53102 μM. | SANGER | ||
| Daoy | Growth Inhibition Assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50 = 0.53222 μM. | SANGER | ||
| MHH-PREB-1 | Growth Inhibition Assay | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50 = 0.53311 μM. | SANGER | ||
| VM-CUB-1 | Growth Inhibition Assay | Inhibition of human VM-CUB-1 cell growth in a cell viability assay, IC50 = 0.53346 μM. | SANGER | ||
| KP-4 | Growth Inhibition Assay | Inhibition of human KP-4 cell growth in a cell viability assay, IC50 = 0.53574 μM. | SANGER | ||
| NCI-H1623 | Growth Inhibition Assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50 = 0.536 μM. | SANGER | ||
| OCI-AML2 | Growth Inhibition Assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 0.54502 μM. | SANGER | ||
| C-33-A | Growth Inhibition Assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50 = 0.55083 μM. | SANGER | ||
| NCI-H1355 | Growth Inhibition Assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 0.55554 μM. | SANGER | ||
| SK-HEP-1 | Growth Inhibition Assay | Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50 = 0.55641 μM. | SANGER | ||
| EC-GI-10 | Growth Inhibition Assay | Inhibition of human EC-GI-10 cell growth in a cell viability assay, IC50 = 0.55698 μM. | SANGER | ||
| HUTU-80 | Growth Inhibition Assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50 = 0.56122 μM. | SANGER | ||
| KYSE-180 | Growth Inhibition Assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50 = 0.56471 μM. | SANGER | ||
| CAL-51 | Growth Inhibition Assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50 = 0.57064 μM. | SANGER | ||
| DU-4475 | Growth Inhibition Assay | Inhibition of human DU-4475 cell growth in a cell viability assay, IC50 = 0.5754 μM. | SANGER | ||
| NUGC-3 | Growth Inhibition Assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 0.58891 μM. | SANGER | ||
| NCI-H2228 | Growth Inhibition Assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 0.59651 μM. | SANGER | ||
| RKO | Growth Inhibition Assay | Inhibition of human RKO cell growth in a cell viability assay, IC50 = 0.59858 μM. | SANGER | ||
| PC-14 | Growth Inhibition Assay | Inhibition of human PC-14 cell growth in a cell viability assay, IC50 = 0.6095 μM. | SANGER | ||
| TI-73 | Growth Inhibition Assay | Inhibition of human TI-73 cell growth in a cell viability assay, IC50 = 0.61266 μM. | SANGER | ||
| CW-2 | Growth Inhibition Assay | Inhibition of human CW-2 cell growth in a cell viability assay, IC50 = 0.61279 μM. | SANGER | ||
| SN12C | Growth Inhibition Assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50 = 0.62292 μM. | SANGER | ||
| M14 | Growth Inhibition Assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 0.63224 μM. | SANGER | ||
| KOSC-2 | Growth Inhibition Assay | Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50 = 0.64309 μM. | SANGER | ||
| G-402 | Growth Inhibition Assay | Inhibition of human G-402 cell growth in a cell viability assay, IC50 = 0.64977 μM. | SANGER | ||
| TYK-nu | Growth Inhibition Assay | Inhibition of human TYK-nu cell growth in a cell viability assay, IC50 = 0.66085 μM. | SANGER | ||
| UACC-62 | Growth Inhibition Assay | Inhibition of human UACC-62 cell growth in a cell viability assay, IC50 = 0.66553 μM. | SANGER | ||
| EW-22 | Growth Inhibition Assay | Inhibition of human EW-22 cell growth in a cell viability assay, IC50 = 0.66762 μM. | SANGER | ||
| 786-0 | Growth Inhibition Assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 0.66871 μM. | SANGER | ||
| LoVo | Growth Inhibition Assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 0.67124 μM. | SANGER | ||
| NCI-H1299 | Growth Inhibition Assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50 = 0.67177 μM. | SANGER | ||
| Saos-2 | Growth Inhibition Assay | Inhibition of human Saos-2 cell growth in a cell viability assay, IC50 = 0.6817 μM. | SANGER | ||
| SJRH30 | Growth Inhibition Assay | Inhibition of human SJRH30 cell growth in a cell viability assay, IC50 = 0.68338 μM. | SANGER | ||
| A2058 | Growth Inhibition Assay | Inhibition of human A2058 cell growth in a cell viability assay, IC50 = 0.68678 μM. | SANGER | ||
| HO-1-N-1 | Growth Inhibition Assay | Inhibition of human HO-1-N-1 cell growth in a cell viability assay, IC50 = 0.69055 μM. | SANGER | ||
| SF126 | Growth Inhibition Assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50 = 0.69317 μM. | SANGER | ||
| LS-411N | Growth Inhibition Assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 0.69527 μM. | SANGER | ||
| RXF393 | Growth Inhibition Assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50 = 0.70032 μM. | SANGER | ||
| CAL-62 | Growth Inhibition Assay | Inhibition of human CAL-62 cell growth in a cell viability assay, IC50 = 0.70983 μM. | SANGER | ||
| SF539 | Growth Inhibition Assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 0.71677 μM. | SANGER | ||
| SW756 | Growth Inhibition Assay | Inhibition of human SW756 cell growth in a cell viability assay, IC50 = 0.71942 μM. | SANGER | ||
| ES6 | Growth Inhibition Assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50 = 0.72144 μM. | SANGER | ||
| MHH-NB-11 | Growth Inhibition Assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 0.72787 μM. | SANGER | ||
| A388 | Growth Inhibition Assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 0.73992 μM. | SANGER | ||
| RPMI-8866 | Growth Inhibition Assay | Inhibition of human RPMI-8866 cell growth in a cell viability assay, IC50 = 0.74014 μM. | SANGER | ||
| HD-MY-Z | Growth Inhibition Assay | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50 = 0.74471 μM. | SANGER | ||
| G-401 | Growth Inhibition Assay | Inhibition of human G-401 cell growth in a cell viability assay, IC50 = 0.75823 μM. | SANGER | ||
| EW-24 | Growth Inhibition Assay | Inhibition of human EW-24 cell growth in a cell viability assay, IC50 = 0.79393 μM. | SANGER | ||
| COR-L23 | Growth Inhibition Assay | Inhibition of human COR-L23 cell growth in a cell viability assay, IC50 = 0.79673 μM. | SANGER | ||
| NCI-H1437 | Growth Inhibition Assay | Inhibition of human NCI-H1437 cell growth in a cell viability assay, IC50 = 0.79806 μM. | SANGER | ||
| SK-MEL-28 | Growth Inhibition Assay | Inhibition of human SK-MEL-28 cell growth in a cell viability assay, IC50 = 0.79873 μM. | SANGER | ||
| PANC-10-05 | Growth Inhibition Assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50 = 0.80176 μM. | SANGER | ||
| EoL-1-cell | Growth Inhibition Assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50 = 0.8031 μM. | SANGER | ||
| D-336MG | Growth Inhibition Assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50 = 0.80494 μM. | SANGER | ||
| SK-MES-1 | Growth Inhibition Assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 0.80682 μM. | SANGER | ||
| COLO-668 | Growth Inhibition Assay | Inhibition of human COLO-668 cell growth in a cell viability assay, IC50 = 0.80916 μM. | SANGER | ||
| BE-13 | Growth Inhibition Assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50 = 0.8245 μM. | SANGER | ||
| EW-3 | Growth Inhibition Assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50 = 0.82999 μM. | SANGER | ||
| OMC-1 | Growth Inhibition Assay | Inhibition of human OMC-1 cell growth in a cell viability assay, IC50 = 0.83236 μM. | SANGER | ||
| Hs-578-T | Growth Inhibition Assay | Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50 = 0.83886 μM. | SANGER | ||
| A3-KAW | Growth Inhibition Assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 0.84424 μM. | SANGER | ||
| KYSE-270 | Growth Inhibition Assay | Inhibition of human KYSE-270 cell growth in a cell viability assay, IC50 = 0.84868 μM. | SANGER | ||
| HuP-T3 | Growth Inhibition Assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 0.85567 μM. | SANGER | ||
| GCT | Growth Inhibition Assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 0.85568 μM. | SANGER | ||
| SiHa | Growth Inhibition Assay | Inhibition of human SiHa cell growth in a cell viability assay, IC50 = 0.85606 μM. | SANGER | ||
| Ramos-2G6-4C10 | Growth Inhibition Assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 0.86757 μM. | SANGER | ||
| DEL | Growth Inhibition Assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 0.87485 μM. | SANGER | ||
| SNU-423 | Growth Inhibition Assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50 = 0.8808 μM. | SANGER | ||
| PANC-03-27 | Growth Inhibition Assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 0.89662 μM. | SANGER | ||
| BHY | Growth Inhibition Assay | Inhibition of human BHY cell growth in a cell viability assay, IC50 = 0.89762 μM. | SANGER | ||
| DOK | Growth Inhibition Assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 0.90446 μM. | SANGER | ||
| SKG-IIIa | Growth Inhibition Assay | Inhibition of human SKG-IIIa cell growth in a cell viability assay, IC50 = 0.91503 μM. | SANGER | ||
| AGS | Growth Inhibition Assay | Inhibition of human AGS cell growth in a cell viability assay, IC50 = 0.91755 μM. | SANGER | ||
| MN-60 | Growth Inhibition Assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 0.93484 μM. | SANGER | ||
| CAL-54 | Growth Inhibition Assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 0.94033 μM. | SANGER | ||
| KMOE-2 | Growth Inhibition Assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50 = 0.94389 μM. | SANGER | ||
| SCC-4 | Growth Inhibition Assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 0.96513 μM. | SANGER | ||
| CAL-39 | Growth Inhibition Assay | Inhibition of human CAL-39 cell growth in a cell viability assay, IC50 = 0.99829 μM. | SANGER | ||
| CHL-1 | Growth Inhibition Assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50 = 1.04316 μM. | SANGER | ||
| NCI-H2030 | Growth Inhibition Assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50 = 1.04946 μM. | SANGER | ||
| COLO-792 | Growth Inhibition Assay | Inhibition of human COLO-792 cell growth in a cell viability assay, IC50 = 1.05355 μM. | SANGER | ||
| CFPAC-1 | Growth Inhibition Assay | Inhibition of human CFPAC-1 cell growth in a cell viability assay, IC50 = 1.05515 μM. | SANGER | ||
| NKM-1 | Growth Inhibition Assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50 = 1.06403 μM. | SANGER | ||
| SK-N-DZ | Growth Inhibition Assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50 = 1.07213 μM. | SANGER | ||
| HC-1 | Growth Inhibition Assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50 = 1.07779 μM. | SANGER | ||
| SCC-15 | Growth Inhibition Assay | Inhibition of human SCC-15 cell growth in a cell viability assay, IC50 = 1.08069 μM. | SANGER | ||
| D-247MG | Growth Inhibition Assay | Inhibition of human D-247MG cell growth in a cell viability assay, IC50 = 1.08967 μM. | SANGER | ||
| KYSE-450 | Growth Inhibition Assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50 = 1.09059 μM. | SANGER | ||
| Becker | Growth Inhibition Assay | Inhibition of human Becker cell growth in a cell viability assay, IC50 = 1.09665 μM. | SANGER | ||
| EGI-1 | Growth Inhibition Assay | Inhibition of human EGI-1 cell growth in a cell viability assay, IC50 = 1.10918 μM. | SANGER | ||
| U251 | Growth Inhibition Assay | Inhibition of human U251 cell growth in a cell viability assay, IC50 = 1.12999 μM. | SANGER | ||
| KG-1 | Growth Inhibition Assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 1.15685 μM. | SANGER | ||
| NH-12 | Growth Inhibition Assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 1.16227 μM. | SANGER | ||
| D-263MG | Growth Inhibition Assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50 = 1.1717 μM. | SANGER | ||
| A4-Fuk | Growth Inhibition Assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50 = 1.17349 μM. | SANGER | ||
| CAL-33 | Growth Inhibition Assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50 = 1.17622 μM. | SANGER | ||
| NCI-H23 | Growth Inhibition Assay | Inhibition of human NCI-H23 cell growth in a cell viability assay, IC50 = 1.19572 μM. | SANGER | ||
| EW-11 | Growth Inhibition Assay | Inhibition of human EW-11 cell growth in a cell viability assay, IC50 = 1.21388 μM. | SANGER | ||
| HT-144 | Growth Inhibition Assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 1.23101 μM. | SANGER | ||
| 647-V | Growth Inhibition Assay | Inhibition of human 647-V cell growth in a cell viability assay, IC50 = 1.23274 μM. | SANGER | ||
| Mewo | Growth Inhibition Assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 1.23969 μM. | SANGER | ||
| OAW-42 | Growth Inhibition Assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50 = 1.24927 μM. | SANGER | ||
| U031 | Growth Inhibition Assay | Inhibition of human U031 cell growth in a cell viability assay, IC50 = 1.25079 μM. | SANGER | ||
| RD | Growth Inhibition Assay | Inhibition of human RD cell growth in a cell viability assay, IC50 = 1.27311 μM. | SANGER | ||
| PC-3 | Growth Inhibition Assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50 = 1.27636 μM. | SANGER | ||
| MC116 | Growth Inhibition Assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50 = 1.28349 μM. | SANGER | ||
| LNCaP-Clone-FGC | Growth Inhibition Assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50 = 1.31198 μM. | SANGER | ||
| SK-LU-1 | Growth Inhibition Assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50 = 1.31214 μM. | SANGER | ||
| MPP-89 | Growth Inhibition Assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50 = 1.31316 μM. | SANGER | ||
| SW780 | Growth Inhibition Assay | Inhibition of human SW780 cell growth in a cell viability assay, IC50 = 1.32041 μM. | SANGER | ||
| HuO-3N1 | Growth Inhibition Assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50 = 1.32628 μM. | SANGER | ||
| L-363 | Growth Inhibition Assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 1.33929 μM. | SANGER | ||
| VMRC-RCZ | Growth Inhibition Assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50 = 1.35399 μM. | SANGER | ||
| SF268 | Growth Inhibition Assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50 = 1.36068 μM. | SANGER | ||
| DOHH-2 | Growth Inhibition Assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50 = 1.3786 μM. | SANGER | ||
| HT-3 | Growth Inhibition Assay | Inhibition of human HT-3 cell growth in a cell viability assay, IC50 = 1.38152 μM. | SANGER | ||
| FTC-133 | Growth Inhibition Assay | Inhibition of human FTC-133 cell growth in a cell viability assay, IC50 = 1.38559 μM. | SANGER | ||
| MDA-MB-157 | Growth Inhibition Assay | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50 = 1.38917 μM. | SANGER | ||
| AsPC-1 | Growth Inhibition Assay | Inhibition of human AsPC-1 cell growth in a cell viability assay, IC50 = 1.39216 μM. | SANGER | ||
| NCI-H1792 | Growth Inhibition Assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50 = 1.42426 μM. | SANGER | ||
| MZ2-MEL | Growth Inhibition Assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 1.43438 μM. | SANGER | ||
| EPLC-272H | Growth Inhibition Assay | Inhibition of human EPLC-272H cell growth in a cell viability assay, IC50 = 1.44992 μM. | SANGER | ||
| JVM-3 | Growth Inhibition Assay | Inhibition of human JVM-3 cell growth in a cell viability assay, IC50 = 1.4541 μM. | SANGER | ||
| HSC-2 | Growth Inhibition Assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50 = 1.45612 μM. | SANGER | ||
| DMS-273 | Growth Inhibition Assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50 = 1.45632 μM. | SANGER | ||
| AM-38 | Growth Inhibition Assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50 = 1.46755 μM. | SANGER | ||
| MIA-PaCa-2 | Growth Inhibition Assay | Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50 = 1.48862 μM. | SANGER | ||
| NB7 | Growth Inhibition Assay | Inhibition of human NB7 cell growth in a cell viability assay, IC50 = 1.51552 μM. | SANGER | ||
| ABC-1 | Growth Inhibition Assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50 = 1.52053 μM. | SANGER | ||
| EFO-21 | Growth Inhibition Assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50 = 1.54986 μM. | SANGER | ||
| NCI-H1666 | Growth Inhibition Assay | Inhibition of human NCI-H1666 cell growth in a cell viability assay, IC50 = 1.5762 μM. | SANGER | ||
| OS-RC-2 | Growth Inhibition Assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50 = 1.58228 μM. | SANGER | ||
| HLE | Growth Inhibition Assay | Inhibition of human HLE cell growth in a cell viability assay, IC50 = 1.59175 μM. | SANGER | ||
| DoTc2-4510 | Growth Inhibition Assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50 = 1.59856 μM. | SANGER | ||
| J82 | Growth Inhibition Assay | Inhibition of human J82 cell growth in a cell viability assay, IC50 = 1.61802 μM. | SANGER | ||
| SW900 | Growth Inhibition Assay | Inhibition of human SW900 cell growth in a cell viability assay, IC50 = 1.62161 μM. | SANGER | ||
| MKN45 | Growth Inhibition Assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50 = 1.64811 μM. | SANGER | ||
| GI-ME-N | Growth Inhibition Assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50 = 1.65967 μM. | SANGER | ||
| DMS-114 | Growth Inhibition Assay | Inhibition of human DMS-114 cell growth in a cell viability assay, IC50 = 1.68124 μM. | SANGER | ||
| HT-1376 | Growth Inhibition Assay | Inhibition of human HT-1376 cell growth in a cell viability assay, IC50 = 1.68168 μM. | SANGER | ||
| T98G | Growth Inhibition Assay | Inhibition of human T98G cell growth in a cell viability assay, IC50 = 1.71811 μM. | SANGER | ||
| SW1710 | Growth Inhibition Assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50 = 1.72915 μM. | SANGER | ||
| TGBC11TKB | Growth Inhibition Assay | Inhibition of human TGBC11TKB cell growth in a cell viability assay, IC50 = 1.73145 μM. | SANGER | ||
| TK10 | Growth Inhibition Assay | Inhibition of human TK10 cell growth in a cell viability assay, IC50 = 1.73331 μM. | SANGER | ||
| NCI-H661 | Growth Inhibition Assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50 = 1.73446 μM. | SANGER | ||
| MKN1 | Growth Inhibition Assay | Inhibition of human MKN1 cell growth in a cell viability assay, IC50 = 1.73948 μM. | SANGER | ||
| U-87-MG | Growth Inhibition Assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50 = 1.74257 μM. | SANGER | ||
| RERF-LC-MS | Growth Inhibition Assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50 = 1.76445 μM. | SANGER | ||
| NCI-H1581 | Growth Inhibition Assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50 = 1.76955 μM. | SANGER | ||
| IGR-1 | Growth Inhibition Assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 1.78279 μM. | SANGER | ||
| TE-9 | Growth Inhibition Assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50 = 1.78754 μM. | SANGER | ||
| HEC-1 | Growth Inhibition Assay | Inhibition of human HEC-1 cell growth in a cell viability assay, IC50 = 1.78799 μM. | SANGER | ||
| IGROV-1 | Growth Inhibition Assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50 = 1.78989 μM. | SANGER | ||
| OE33 | Growth Inhibition Assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50 = 1.80243 μM. | SANGER | ||
| MZ1-PC | Growth Inhibition Assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 1.80338 μM. | SANGER | ||
| NCI-H28 | Growth Inhibition Assay | Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50 = 1.82221 μM. | SANGER | ||
| M059J | Growth Inhibition Assay | Inhibition of human M059J cell growth in a cell viability assay, IC50 = 1.82297 μM. | SANGER | ||
| AN3-CA | Growth Inhibition Assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 1.84009 μM. | SANGER | ||
| MV-4-11 | Growth Inhibition Assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 1.8467 μM. | SANGER | ||
| TGBC24TKB | Growth Inhibition Assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 1.8517 μM. | SANGER | ||
| KYSE-70 | Growth Inhibition Assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50 = 1.85716 μM. | SANGER | ||
| COLO-829 | Growth Inhibition Assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50 = 1.86471 μM. | SANGER | ||
| HCC38 | Growth Inhibition Assay | Inhibition of human HCC38 cell growth in a cell viability assay, IC50 = 1.87965 μM. | SANGER | ||
| NOS-1 | Growth Inhibition Assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50 = 1.90764 μM. | SANGER | ||
| CAL-27 | Growth Inhibition Assay | Inhibition of human CAL-27 cell growth in a cell viability assay, IC50 = 1.92856 μM. | SANGER | ||
| EFO-27 | Growth Inhibition Assay | Inhibition of human EFO-27 cell growth in a cell viability assay, IC50 = 1.93966 μM. | SANGER | ||
| NMC-G1 | Growth Inhibition Assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50 = 1.95708 μM. | SANGER | ||
| EW-13 | Growth Inhibition Assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50 = 1.9815 μM. | SANGER | ||
| MDA-MB-175-VII | Growth Inhibition Assay | Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay, IC50 = 1.99141 μM. | SANGER | ||
| MCF7 | Growth Inhibition Assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50 = 2.00248 μM. | SANGER | ||
| Detroit562 | Growth Inhibition Assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50 = 2.0621 μM. | SANGER | ||
| KNS-62 | Growth Inhibition Assay | Inhibition of human KNS-62 cell growth in a cell viability assay, IC50 = 2.07553 μM. | SANGER | ||
| MDA-MB-453 | Growth Inhibition Assay | Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50 = 2.10739 μM. | SANGER | ||
| KASUMI-1 | Growth Inhibition Assay | Inhibition of human KASUMI-1 cell growth in a cell viability assay, IC50 = 2.16268 μM. | SANGER | ||
| FADU | Growth Inhibition Assay | Inhibition of human FADU cell growth in a cell viability assay, IC50 = 2.16998 μM. | SANGER | ||
| KYSE-410 | Growth Inhibition Assay | Inhibition of human KYSE-410 cell growth in a cell viability assay, IC50 = 2.19194 μM. | SANGER | ||
| IST-SL1 | Growth Inhibition Assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50 = 2.20154 μM. | SANGER | ||
| NCI-H2009 | Growth Inhibition Assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50 = 2.25295 μM. | SANGER | ||
| ETK-1 | Growth Inhibition Assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50 = 2.3042 μM. | SANGER | ||
| COLO-741 | Growth Inhibition Assay | Inhibition of human COLO-741 cell growth in a cell viability assay, IC50 = 2.32544 μM. | SANGER | ||
| NOMO-1 | Growth Inhibition Assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 2.33232 μM. | SANGER | ||
| KU812 | Growth Inhibition Assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50 = 2.3578 μM. | SANGER | ||
| MEG-01 | Growth Inhibition Assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 2.38965 μM. | SANGER | ||
| NCI-H1755 | Growth Inhibition Assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50 = 2.41912 μM. | SANGER | ||
| MKN28 | Growth Inhibition Assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50 = 2.41927 μM. | SANGER | ||
| HL-60 | Growth Inhibition Assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 2.44486 μM. | SANGER | ||
| SCC-9 | Growth Inhibition Assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 2.44796 μM. | SANGER | ||
| NCI-H226 | Growth Inhibition Assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 2.52099 μM. | SANGER | ||
| KYSE-520 | Growth Inhibition Assay | Inhibition of human KYSE-520 cell growth in a cell viability assay, IC50 = 2.54159 μM. | SANGER | ||
| MG-63 | Growth Inhibition Assay | Inhibition of human MG-63 cell growth in a cell viability assay, IC50 = 2.55986 μM. | SANGER | ||
| HCC2998 | Growth Inhibition Assay | Inhibition of human HCC2998 cell growth in a cell viability assay, IC50 = 2.57816 μM. | SANGER | ||
| DBTRG-05MG | Growth Inhibition Assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50 = 2.61987 μM. | SANGER | ||
| HH | Growth Inhibition Assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 2.64005 μM. | SANGER | ||
| CAS-1 | Growth Inhibition Assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50 = 2.64247 μM. | SANGER | ||
| NCI-N87 | Growth Inhibition Assay | Inhibition of human NCI-N87 cell growth in a cell viability assay, IC50 = 2.67652 μM. | SANGER | ||
| SW1573 | Growth Inhibition Assay | Inhibition of human SW1573 cell growth in a cell viability assay, IC50 = 2.67671 μM. | SANGER | ||
| LU-134-A | Growth Inhibition Assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50 = 2.72472 μM. | SANGER | ||
| KYSE-140 | Growth Inhibition Assay | Inhibition of human KYSE-140 cell growth in a cell viability assay, IC50 = 2.7526 μM. | SANGER | ||
| 22RV1 | Growth Inhibition Assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50 = 2.7581 μM. | SANGER | ||
| SW626 | Growth Inhibition Assay | Inhibition of human SW626 cell growth in a cell viability assay, IC50 = 2.7603 μM. | SANGER | ||
| MS-1 | Growth Inhibition Assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 2.76845 μM. | SANGER | ||
| ACN | Growth Inhibition Assay | Inhibition of human ACN cell growth in a cell viability assay, IC50 = 2.79438 μM. | SANGER | ||
| GCIY | Growth Inhibition Assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50 = 2.80234 μM. | SANGER | ||
| Ca-Ski | Growth Inhibition Assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50 = 2.86167 μM. | SANGER | ||
| SK-MEL-1 | Growth Inhibition Assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50 = 2.90249 μM. | SANGER | ||
| S-117 | Growth Inhibition Assay | Inhibition of human S-117 cell growth in a cell viability assay, IC50 = 2.92422 μM. | SANGER | ||
| HuCCT1 | Growth Inhibition Assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 2.93645 μM. | SANGER | ||
| TE-11 | Growth Inhibition Assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 2.95427 μM. | SANGER | ||
| MFH-ino | Growth Inhibition Assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50 = 2.956 μM. | SANGER | ||
| MDA-MB-415 | Growth Inhibition Assay | Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50 = 2.9585 μM. | SANGER | ||
| EFM-19 | Growth Inhibition Assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50 = 2.98059 μM. | SANGER | ||
| NCI-H2405 | Growth Inhibition Assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50 = 3.00449 μM. | SANGER | ||
| HCC1395 | Growth Inhibition Assay | Inhibition of human HCC1395 cell growth in a cell viability assay, IC50 = 3.0071 μM. | SANGER | ||
| NCI-H2452 | Growth Inhibition Assay | Inhibition of human NCI-H2452 cell growth in a cell viability assay, IC50 = 3.12218 μM. | SANGER | ||
| CAL-72 | Growth Inhibition Assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50 = 3.1454 μM. | SANGER | ||
| LB2518-MEL | Growth Inhibition Assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50 = 3.20734 μM. | SANGER | ||
| NCI-H1395 | Growth Inhibition Assay | Inhibition of human NCI-H1395 cell growth in a cell viability assay, IC50 = 3.24713 μM. | SANGER | ||
| SCH | Growth Inhibition Assay | Inhibition of human SCH cell growth in a cell viability assay, IC50 = 3.26893 μM. | SANGER | ||
| CAPAN-1 | Growth Inhibition Assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50 = 3.27528 μM. | SANGER | ||
| HT55 | Growth Inhibition Assay | Inhibition of human HT55 cell growth in a cell viability assay, IC50 = 3.28944 μM. | SANGER | ||
| NCI-H747 | Growth Inhibition Assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 3.29752 μM. | SANGER | ||
| TCCSUP | Growth Inhibition Assay | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50 = 3.30446 μM. | SANGER | ||
| SW1088 | Growth Inhibition Assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50 = 3.31361 μM. | SANGER | ||
| NCI-H2170 | Growth Inhibition Assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50 = 3.35641 μM. | SANGER | ||
| D-392MG | Growth Inhibition Assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50 = 3.40336 μM. | SANGER | ||
| DSH1 | Growth Inhibition Assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50 = 3.40884 μM. | SANGER | ||
| AU565 | Growth Inhibition Assay | Inhibition of human AU565 cell growth in a cell viability assay, IC50 = 3.47021 μM. | SANGER | ||
| A172 | Growth Inhibition Assay | Inhibition of human A172 cell growth in a cell viability assay, IC50 = 3.5178 μM. | SANGER | ||
| HT-29 | Growth Inhibition Assay | Inhibition of human HT-29 cell growth in a cell viability assay, IC50 = 3.52424 μM. | SANGER | ||
| SK-NEP-1 | Growth Inhibition Assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 3.54517 μM. | SANGER | ||
| IST-MES1 | Growth Inhibition Assay | Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50 = 3.55449 μM. | SANGER | ||
| KARPAS-45 | Growth Inhibition Assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 3.60977 μM. | SANGER | ||
| HCC70 | Growth Inhibition Assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 3.62428 μM. | SANGER | ||
| BPH-1 | Growth Inhibition Assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50 = 3.64205 μM. | SANGER | ||
| 8505C | Growth Inhibition Assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50 = 3.70201 μM. | SANGER | ||
| A498 | Growth Inhibition Assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 3.72949 μM. | SANGER | ||
| SW962 | Growth Inhibition Assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 3.73962 μM. | SANGER | ||
| SW1990 | Growth Inhibition Assay | Inhibition of human SW1990 cell growth in a cell viability assay, IC50 = 3.82795 μM. | SANGER | ||
| HuO9 | Growth Inhibition Assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50 = 3.85347 μM. | SANGER | ||
| NCI-H446 | Growth Inhibition Assay | Inhibition of human NCI-H446 cell growth in a cell viability assay, IC50 = 3.9054 μM. | SANGER | ||
| TE-10 | Growth Inhibition Assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50 = 3.90867 μM. | SANGER | ||
| WM-115 | Growth Inhibition Assay | Inhibition of human WM-115 cell growth in a cell viability assay, IC50 = 3.99333 μM. | SANGER | ||
| RCM-1 | Growth Inhibition Assay | Inhibition of human RCM-1 cell growth in a cell viability assay, IC50 = 4.01309 μM. | SANGER | ||
| SK-MEL-2 | Growth Inhibition Assay | Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50 = 4.0281 μM. | SANGER | ||
| SF295 | Growth Inhibition Assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50 = 4.03391 μM. | SANGER | ||
| KINGS-1 | Growth Inhibition Assay | Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50 = 4.05297 μM. | SANGER | ||
| NCI-H2052 | Growth Inhibition Assay | Inhibition of human NCI-H2052 cell growth in a cell viability assay, IC50 = 4.05679 μM. | SANGER | ||
| NCI-H1650 | Growth Inhibition Assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 4.13216 μM. | SANGER | ||
| U-118-MG | Growth Inhibition Assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 4.15547 μM. | SANGER | ||
| MDA-MB-361 | Growth Inhibition Assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 4.22726 μM. | SANGER | ||
| HCC1419 | Growth Inhibition Assay | Inhibition of human HCC1419 cell growth in a cell viability assay, IC50 = 4.26266 μM. | SANGER | ||
| OCUB-M | Growth Inhibition Assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50 = 4.28414 μM. | SANGER | ||
| BxPC-3 | Growth Inhibition Assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 4.29914 μM. | SANGER | ||
| HT-1197 | Growth Inhibition Assay | Inhibition of human HT-1197 cell growth in a cell viability assay, IC50 = 4.31327 μM. | SANGER | ||
| NCI-H526 | Growth Inhibition Assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 4.33328 μM. | SANGER | ||
| KS-1 | Growth Inhibition Assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 4.34468 μM. | SANGER | ||
| NCI-H650 | Growth Inhibition Assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50 = 4.35377 μM. | SANGER | ||
| KU-19-19 | Growth Inhibition Assay | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50 = 4.42891 μM. | SANGER | ||
| UACC-257 | Growth Inhibition Assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 4.46437 μM. | SANGER | ||
| TGBC1TKB | Growth Inhibition Assay | Inhibition of human TGBC1TKB cell growth in a cell viability assay, IC50 = 4.5212 μM. | SANGER | ||
| LB831-BLC | Growth Inhibition Assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50 = 4.58569 μM. | SANGER | ||
| SW1783 | Growth Inhibition Assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50 = 4.61383 μM. | SANGER | ||
| NCI-H2347 | Growth Inhibition Assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 4.63698 μM. | SANGER | ||
| RCC10RGB | Growth Inhibition Assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 4.68428 μM. | SANGER | ||
| A101D | Growth Inhibition Assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 4.76358 μM. | SANGER | ||
| NCI-H2087 | Growth Inhibition Assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 4.80595 μM. | SANGER | ||
| NCI-H1651 | Growth Inhibition Assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 4.98474 μM. | SANGER | ||
| SK-N-FI | Growth Inhibition Assay | Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50 = 5.06408 μM. | SANGER | ||
| SW1116 | Growth Inhibition Assay | Inhibition of human SW1116 cell growth in a cell viability assay, IC50 = 5.12 μM. | SANGER | ||
| C3A | Growth Inhibition Assay | Inhibition of human C3A cell growth in a cell viability assay, IC50 = 5.23422 μM. | SANGER | ||
| SNU-449 | Growth Inhibition Assay | Inhibition of human SNU-449 cell growth in a cell viability assay, IC50 = 5.30865 μM. | SANGER | ||
| NCI-H630 | Growth Inhibition Assay | Inhibition of human NCI-H630 cell growth in a cell viability assay, IC50 = 5.34812 μM. | SANGER | ||
| DK-MG | Growth Inhibition Assay | Inhibition of human DK-MG cell growth in a cell viability assay, IC50 = 5.39082 μM. | SANGER | ||
| YAPC | Growth Inhibition Assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 5.44769 μM. | SANGER | ||
| BEN | Growth Inhibition Assay | Inhibition of human BEN cell growth in a cell viability assay, IC50 = 5.44777 μM. | SANGER | ||
| Calu-3 | Growth Inhibition Assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50 = 5.45736 μM. | SANGER | ||
| 8305C | Growth Inhibition Assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 5.46669 μM. | SANGER | ||
| ESS-1 | Growth Inhibition Assay | Inhibition of human ESS-1 cell growth in a cell viability assay, IC50 = 5.47851 μM. | SANGER | ||
| ME-180 | Growth Inhibition Assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50 = 5.48535 μM. | SANGER | ||
| D-502MG | Growth Inhibition Assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50 = 5.49075 μM. | SANGER | ||
| CP50-MEL-B | Growth Inhibition Assay | Inhibition of human CP50-MEL-B cell growth in a cell viability assay, IC50 = 5.59584 μM. | SANGER | ||
| OAW-28 | Growth Inhibition Assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50 = 5.66484 μM. | SANGER | ||
| SCC-25 | Growth Inhibition Assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 5.66836 μM. | SANGER | ||
| NCI-H810 | Growth Inhibition Assay | Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50 = 5.67785 μM. | SANGER | ||
| no-11 | Growth Inhibition Assay | Inhibition of human no-11 cell growth in a cell viability assay, IC50 = 5.81096 μM. | SANGER | ||
| OVCAR-4 | Growth Inhibition Assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 6.07487 μM. | SANGER | ||
| A704 | Growth Inhibition Assay | Inhibition of human A704 cell growth in a cell viability assay, IC50 = 6.13363 μM. | SANGER | ||
| GB-1 | Growth Inhibition Assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 6.14107 μM. | SANGER | ||
| NCI-H358 | Growth Inhibition Assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50 = 6.19117 μM. | SANGER | ||
| A431 | Growth Inhibition Assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 6.26477 μM. | SANGER | ||
| SK-MEL-24 | Growth Inhibition Assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50 = 6.2749 μM. | SANGER | ||
| NB17 | Growth Inhibition Assay | Inhibition of human NB17 cell growth in a cell viability assay, IC50 = 6.44011 μM. | SANGER | ||
| BB49-HNC | Growth Inhibition Assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 6.49529 μM. | SANGER | ||
| NCI-H1573 | Growth Inhibition Assay | Inhibition of human NCI-H1573 cell growth in a cell viability assay, IC50 = 6.70803 μM. | SANGER | ||
| GAK | Growth Inhibition Assay | Inhibition of human GAK cell growth in a cell viability assay, IC50 = 6.8404 μM. | SANGER | ||
| CAL-120 | Growth Inhibition Assay | Inhibition of human CAL-120 cell growth in a cell viability assay, IC50 = 7.07643 μM. | SANGER | ||
| PANC-08-13 | Growth Inhibition Assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50 = 7.78108 μM. | SANGER | ||
| SW1463 | Growth Inhibition Assay | Inhibition of human SW1463 cell growth in a cell viability assay, IC50 = 8.01873 μM. | SANGER | ||
| SW872 | Growth Inhibition Assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50 = 8.07734 μM. | SANGER | ||
| HCT-15 | Growth Inhibition Assay | Inhibition of human HCT-15 cell growth in a cell viability assay, IC50 = 8.12311 μM. | SANGER | ||
| SH-4 | Growth Inhibition Assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 8.14247 μM. | SANGER | ||
| TE-6 | Growth Inhibition Assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50 = 8.24962 μM. | SANGER | ||
| Capan-2 | Growth Inhibition Assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 8.36036 μM. | SANGER | ||
| RO82-W-1 | Growth Inhibition Assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50 = 8.4861 μM. | SANGER | ||
| SW948 | Growth Inhibition Assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 8.56121 μM. | SANGER | ||
| NB12 | Growth Inhibition Assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50 = 8.6577 μM. | SANGER | ||
| NCI-H2342 | Growth Inhibition Assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50 = 8.67749 μM. | SANGER | ||
| PFSK-1 | Growth Inhibition Assay | Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50 = 8.73766 μM. | SANGER | ||
| HPAF-II | Growth Inhibition Assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 8.77154 μM. | SANGER | ||
| MDA-MB-231 | Growth Inhibition Assay | Inhibition of human MDA-MB-231 cell growth in a cell viability assay, IC50 = 8.82383 μM. | SANGER | ||
| KNS-81-FD | Growth Inhibition Assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50 = 9.19714 μM. | SANGER | ||
| NCI-H1563 | Growth Inhibition Assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50 = 9.21672 μM. | SANGER | ||
| MEL-HO | Growth Inhibition Assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50 = 9.31744 μM. | SANGER | ||
| NCI-H2126 | Growth Inhibition Assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50 = 9.32815 μM. | SANGER | ||
| SNB75 | Growth Inhibition Assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50 = 9.36079 μM. | SANGER | ||
| NCI-H1693 | Growth Inhibition Assay | Inhibition of human NCI-H1693 cell growth in a cell viability assay, IC50 = 9.57931 μM. | SANGER | ||
| NCI-H460 | Growth Inhibition Assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50 = 9.6401 μM. | SANGER | ||
| COLO-824 | Growth Inhibition Assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50 = 9.83259 μM. | SANGER | ||
| CAL-12T | Growth Inhibition Assay | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50 = 10.1844 μM. | SANGER | ||
| KM12 | Growth Inhibition Assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 10.2778 μM. | SANGER | ||
| IA-LM | Growth Inhibition Assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50 = 10.4447 μM. | SANGER | ||
| SK-MEL-3 | Growth Inhibition Assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 11.1627 μM. | SANGER | ||
| LB771-HNC | Growth Inhibition Assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50 = 11.1986 μM. | SANGER | ||
| NCI-H2291 | Growth Inhibition Assay | Inhibition of human NCI-H2291 cell growth in a cell viability assay, IC50 = 11.3553 μM. | SANGER | ||
| NCI-H1092 | Growth Inhibition Assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 11.7291 μM. | SANGER | ||
| MMAC-SF | Growth Inhibition Assay | Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50 = 11.9527 μM. | SANGER | ||
| CP66-MEL | Growth Inhibition Assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50 = 11.9806 μM. | SANGER | ||
| LAN-6 | Growth Inhibition Assay | Inhibition of human LAN-6 cell growth in a cell viability assay, IC50 = 12.4743 μM. | SANGER | ||
| COLO-684 | Growth Inhibition Assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 12.9893 μM. | SANGER | ||
| NCI-H720 | Growth Inhibition Assay | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50 = 13.1893 μM. | SANGER | ||
| C32 | Growth Inhibition Assay | Inhibition of human C32 cell growth in a cell viability assay, IC50 = 13.2745 μM. | SANGER | ||
| KLE | Growth Inhibition Assay | Inhibition of human KLE cell growth in a cell viability assay, IC50 = 13.3925 μM. | SANGER | ||
| NCI-H1648 | Growth Inhibition Assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50 = 13.6829 μM. | SANGER | ||
| SBC-1 | Growth Inhibition Assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50 = 14.2024 μM. | SANGER | ||
| RVH-421 | Growth Inhibition Assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50 = 14.3302 μM. | SANGER | ||
| LB373-MEL-D | Growth Inhibition Assay | Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50 = 14.38 μM. | SANGER | ||
| NCI-H441 | Growth Inhibition Assay | Inhibition of human NCI-H441 cell growth in a cell viability assay, IC50 = 14.7391 μM. | SANGER | ||
| ECC10 | Growth Inhibition Assay | Inhibition of human ECC10 cell growth in a cell viability assay, IC50 = 15.1731 μM. | SANGER | ||
| SNU-C2B | Growth Inhibition Assay | Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50 = 15.4643 μM. | SANGER | ||
| U-266 | Growth Inhibition Assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 15.5375 μM. | SANGER | ||
| HOP-62 | Growth Inhibition Assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50 = 16.6013 μM. | SANGER | ||
| CaR-1 | Growth Inhibition Assay | Inhibition of human CaR-1 cell growth in a cell viability assay, IC50 = 16.6623 μM. | SANGER | ||
| LN-405 | Growth Inhibition Assay | Inhibition of human LN-405 cell growth in a cell viability assay, IC50 = 17.1486 μM. | SANGER | ||
| DJM-1 | Growth Inhibition Assay | Inhibition of human DJM-1 cell growth in a cell viability assay, IC50 = 17.17 μM. | SANGER | ||
| KY821 | Growth Inhibition Assay | Inhibition of human KY821 cell growth in a cell viability assay, IC50 = 17.2008 μM. | SANGER | ||
| RMG-I | Growth Inhibition Assay | Inhibition of human RMG-I cell growth in a cell viability assay, IC50 = 18.5568 μM. | SANGER | ||
| SBC-5 | Growth Inhibition Assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50 = 19.5065 μM. | SANGER | ||
| NCI-H1838 | Growth Inhibition Assay | Inhibition of human NCI-H1838 cell growth in a cell viability assay, IC50 = 19.9055 μM. | SANGER | ||
| NB6 | Growth Inhibition Assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50 = 20.2853 μM. | SANGER | ||
| OVCAR-3 | Growth Inhibition Assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50 = 20.3154 μM. | SANGER | ||
| MKN7 | Growth Inhibition Assay | Inhibition of human MKN7 cell growth in a cell viability assay, IC50 = 20.3314 μM. | SANGER | ||
| HCC1569 | Growth Inhibition Assay | Inhibition of human HCC1569 cell growth in a cell viability assay, IC50 = 21.9995 μM. | SANGER | ||
| OE19 | Growth Inhibition Assay | Inhibition of human OE19 cell growth in a cell viability assay, IC50 = 22.4401 μM. | SANGER | ||
| LU-139 | Growth Inhibition Assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50 = 22.4402 μM. | SANGER | ||
| NB13 | Growth Inhibition Assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50 = 22.504 μM. | SANGER | ||
| SW1417 | Growth Inhibition Assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 22.5851 μM. | SANGER | ||
| NCI-H1975 | Growth Inhibition Assay | Inhibition of human NCI-H1975 cell growth in a cell viability assay, IC50 = 23.8807 μM. | SANGER | ||
| LCLC-103H | Growth Inhibition Assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50 = 24.5205 μM. | SANGER | ||
| HuH-7 | Growth Inhibition Assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 24.6147 μM. | SANGER | ||
| LU-135 | Growth Inhibition Assay | Inhibition of human LU-135 cell growth in a cell viability assay, IC50 = 26.5933 μM. | SANGER | ||
| NCI-H1793 | Growth Inhibition Assay | Inhibition of human NCI-H1793 cell growth in a cell viability assay, IC50 = 26.6093 μM. | SANGER | ||
| SK-MEL-30 | Growth Inhibition Assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50 = 27.3999 μM. | SANGER | ||
| HCC1937 | Growth Inhibition Assay | Inhibition of human HCC1937 cell growth in a cell viability assay, IC50 = 27.5398 μM. | SANGER | ||
| 639-V | Growth Inhibition Assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 27.5914 μM. | SANGER | ||
| HCC1187 | Growth Inhibition Assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50 = 28.6541 μM. | SANGER | ||
| no-10 | Growth Inhibition Assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50 = 29.8844 μM. | SANGER | ||
| HCC1954 | Growth Inhibition Assay | Inhibition of human HCC1954 cell growth in a cell viability assay, IC50 = 30.3937 μM. | SANGER | ||
| SW837 | Growth Inhibition Assay | Inhibition of human SW837 cell growth in a cell viability assay, IC50 = 30.8538 μM. | SANGER | ||
| CCRF-CEM | Growth Inhibition Assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50 = 32.1211 μM. | SANGER | ||
| CAMA-1 | Growth Inhibition Assay | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50 = 32.163 μM. | SANGER | ||
| T47D | Growth Inhibition Assay | Inhibition of human T47D cell growth in a cell viability assay, IC50 = 32.1884 μM. | SANGER | ||
| KNS-42 | Growth Inhibition Assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50 = 32.2443 μM. | SANGER | ||
| COLO-320-HSR | Growth Inhibition Assay | Inhibition of human COLO-320-HSR cell growth in a cell viability assay, IC50 = 32.4293 μM. | SANGER | ||
| UACC-893 | Growth Inhibition Assay | Inhibition of human UACC-893 cell growth in a cell viability assay, IC50 = 32.6355 μM. | SANGER | ||
| KALS-1 | Growth Inhibition Assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50 = 33.3928 μM. | SANGER | ||
| ChaGo-K-1 | Growth Inhibition Assay | Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50 = 33.7009 μM. | SANGER | ||
| MFM-223 | Growth Inhibition Assay | Inhibition of human MFM-223 cell growth in a cell viability assay, IC50 = 34.0243 μM. | SANGER | ||
| C8166 | Growth Inhibition Assay | Inhibition of human C8166 cell growth in a cell viability assay, IC50 = 40.3675 μM. | SANGER | ||
| NCI-H2029 | Growth Inhibition Assay | Inhibition of human NCI-H2029 cell growth in a cell viability assay, IC50 = 40.9728 μM. | SANGER | ||
| DMS-79 | Growth Inhibition Assay | Inhibition of human DMS-79 cell growth in a cell viability assay, IC50 = 41.1583 μM. | SANGER | ||
| T84 | Growth Inhibition Assay | Inhibition of human T84 cell growth in a cell viability assay, IC50 = 41.246 μM. | SANGER | ||
| NCI-H520 | Growth Inhibition Assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50 = 43.4761 μM. | SANGER | ||
| COLO-680N | Growth Inhibition Assay | Inhibition of human COLO-680N cell growth in a cell viability assay, IC50 = 45.2396 μM. | SANGER | ||
| RH-18 | Growth Inhibition Assay | Inhibition of human RH-18 cell growth in a cell viability assay, IC50 = 46.3786 μM. | SANGER | ||
| BT-474 | Growth Inhibition Assay | Inhibition of human BT-474 cell growth in a cell viability assay, IC50 = 49.4631 μM. | SANGER | ||
| 點擊查看更多細胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Cytarabine是一種抗代謝藥，也是DNA synthesis抑制劑，在野生型CCRF-CEM細胞中IC50為16 nM。Cytarabine 可誘導自噬和細胞凋亡。 | ||
|---|---|---|---|
| 特性 | Cytarabine是一系列改變核糖苷的抗癌藥物中的第一個。 | ||
| 靶點 |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | Cytarabine (AraC)磷酸化為含脫氧胞啶激酶(dCK)的三磷酸鹽形式 (Ara-CTP),與dCTP 競爭進入DNA中, 通過抑制DNA和 RNA 聚合酶功能而 抑制DNA合成 。Cytarabine作用于野生型CCRF-CEM 細胞，抑制生長活性比其他急性骨髓性白血病高很多，IC50為 16 nM。[1] 濃度不斷提高的 Cytarabine (IC50 為0.69 μM) 作用于敏感大鼠白血病細胞系RO/1，導致代謝活性降低, 且作用于人類野生型dCK (IC50 為 0.037 μM) 而不是失活型選擇性拼接的dCK形式時增強細胞毒性。[2]10 μM Cytarabine 作用于大鼠交感神經(jīng)元，誘導凋亡, 100 μM 時毒性最高，作用于神經(jīng)元84小時，可殺死80%神經(jīng)元，包含線粒體細胞色素-c的釋放， caspase-3的激活， 抑制p53基因 可降低毒性，刪除bax基因可延遲但是不會阻斷毒性。[3] |
|||
|---|---|---|---|---|
| 激酶實驗 | 體外抑制生長實驗 | |||
| Cytarabine儲存液儲備在無水乙醇中，制備連續(xù)稀釋的Cytarabine。CCRF-CEM 細胞懸浮在含10% FBS, 0.1% Gentamicin,和 1%丙酮酸鈉的RPMI培養(yǎng)基上。 按每mL 3-6×104個細胞密度細胞懸浮在各自培養(yǎng)基中，獲得10 mL細胞懸浮液。合適體積 Cytarabine溶液轉(zhuǎn)移到細胞懸浮液中，再溫育72小時。細胞旋轉(zhuǎn)減慢，再次懸浮在新鮮無Cytarabine培養(yǎng)基中，測定最終細胞數(shù)。通過分析細胞數(shù)與Cytarabine濃度的S曲線擬合, 而測定IC50。 | ||||
| 細胞實驗 | 細胞系 | 大鼠白血病細胞系RCL/0, RO/1和 K7,及人類單核細胞性白血病細胞U937 | ||
| 濃度 | 100 μM 左右 | |||
| 孵育時間 | 24,48和72小時 | |||
| 方法 | 37oC下，不同濃度Cytarabine處理細胞24,48,和72小時。在處理 20,44,或68小時時，加入10 mL細胞增殖試劑WST-1溶液。和WST-1溫育2或4小時后，使用比色分析測定細胞代謝活力,在450 nm處測定吸光值。通過eosin染色計算細胞分裂倍數(shù)，及細胞活性。 |
|||
| 實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
| Western blot | p-mTOR / mTOR / p-S6K / S6K / p-AMPK / AMPK / p-AKT / AKT / p-ERK / ERK |
|
24714637 | |
| Growth inhibition assay | Cell viability |
|
24714637 | |
| 體內(nèi)研究(In Vivo) | ||
| 體內(nèi)研究活性 | Cytarabine高效作用于急性白血病，引起G1/S期停頓和同步化， 且低劑量時提高患白血病Brown Norway大鼠存活時間，說明使用高劑量Cytarabine 與抗人類白血病效果沒有關(guān)系。[4] Cytarabine按 250 mg/kg劑量 作用于妊娠 Slc:Wistar大鼠的胎盤，也引起胎盤生長受阻，且提高胎盤滋養(yǎng)細胞凋亡，處理3小時開始提高，6小時達到最高峰，48小時恢復到對照組水平，且明顯增強 p53蛋白, p53轉(zhuǎn)錄靶點基因，如p21, cyclinG1 ，fas，和 caspase-3活性。[5] |
|
|---|---|---|
| 動物實驗 | Animal Models | 患髓細胞性白血病的Brown Norway大鼠 |
| Dosages | 5-1000 mg/kg | |
| Administration | 靜脈注射 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05697510 | Recruiting | Acute Myeloid Leukemia (AML) |
Nantes University Hospital |
March 16 2023 | Phase 1 |
化學信息&溶解度
| 分子量 | 243.22 | 分子式 | C9H13N3O5 |
| CAS號 | 147-94-4 | SDF | Download Cytarabine SDF |
| Smiles | C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 49 mg/mL ( (201.46 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Water : 49 mg/mL (201.46 mM) Ethanol : Insoluble |
摩爾濃度計算器 |
|
體內(nèi)溶解度 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 | ||||
實驗計算
動物體內(nèi)配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
Tags: buy Cytarabine | Cytarabine supplier | purchase Cytarabine | Cytarabine cost | Cytarabine manufacturer | order Cytarabine | Cytarabine distributor
